

Complete Listing of the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently amended) A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of (a) bathocuproine or a hydrophobic derivative thereof; and (b) one or more pharmaceutically acceptable carriers or diluents; for a time and under conditions to bring about said treatment; and wherein said ~~chelator~~ bathocuproine or hydrophobic derivative thereof reduces, inhibits or otherwise interferes with amyloid beta peptide (A β)-mediated production of radical oxygen species.

2. (Previously presented) The method of claim 1 further comprising administering to the subject an effective amount of indomethacin, or a pharmaceutically acceptable salt thereof.

3 - 36. (Cancelled)

37. (Currently amended) A pharmaceutical composition for treatment of conditions caused by amyloidosis, amyloid beta peptide (A β)-mediated reactive oxygen species (ROS) formation, or both, comprising: (a) bathocuproine or a hydrophobic derivative thereof; (b) indomethacin or a hydrophobic derivative thereof; and ~~(b)~~ (c) one or more pharmaceutically acceptable carriers or diluents.

38 - 52. (Cancelled)

53. (Previously presented) A composition of matter comprising: (a) bathocuproine or a hydrophobic derivative thereof; and (b) indomethacin.

54 - 94. (Cancelled)